Skip to main content

Table 1 pCR in the overall cohort according to breast cancer subtypes

From: Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto

Breast cancer subtype

Patients without pCR (n, %)

Patients with pCR (n,%)

Luminal A-like

893 (93.6)

61 (6.4)

Luminal B-like

329 (86.4)

52 (13.6)

HER2 positive

564 (69.7)

245 (30.3)

TNBC

629 (62.4)

379 (37.6)